Search Patents
  • Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization
    Patent number: 4939149
    Abstract: The present invention relates to a method for desensitizing a subject animal, which comprises administering to the subject animal a therapeutically effective desensitizing amount of resiniferatoxin for desensitizing the subject animal to neurogenic inflammation, to chemically and thermally induced pain and to responses involving sensory afferent pathways sensitive to capsaicin and to responses involving the hypothalamic temperature control region, and a pharmaceutically acceptable carrier therefor.
    Type: Grant
    Filed: October 24, 1988
    Date of Patent: July 3, 1990
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Peter M. Blumberg
  • Compositions and methods for treatment of mild cognitive impairment
    Publication number: 20020173549
    Abstract: A method of treating Mild Cognitive Impairment (MCI) has been discovered. The treatment includes administering an effective amount of a natural product that increases soluble amyloid precursor protein (APPs) expression. Examples of a natural product suitable for the method include, but are not limited to, resveratrol, capsaisin, olvanil, resiniferatoxin, arvanil, linvanil, capsazepine, or combinations of these naturally occurring substances. The treatment can also be used to prevent or alleviate the dementia, or to delay its onset. Moreover, a foodstuff is disclosed that incorporates a natural product useful in treating MCI.
    Type: Application
    Filed: November 8, 2001
    Publication date: November 21, 2002
    Inventors: Richard J. Wurtman, Robert K. K. Lee
  • Inhibition of nuclear transcription factor NF-.kappa.B by caffeic acid phenethyl ester (CAPE), derivatives of CAPE, capsaicin (8-methyl-N-vanillyl-6-nonenamide) and resiniferatoxin
    Patent number: 5981583
    Abstract: The present invention is drawn to the inhibition of activation of NF-.kappa.B by caffeic acid phenethyl ester (CAPE) and two analogues of CAPE. Tumor necrosis factor (TNF) activation of NF-.kappa.B is completely blocked by CAPE in a dose- and time-dependent manner, as is activation by phorbol ester, ceramide, hydrogen peroxide, and okadaic acid. Additionally, capsaicin (8-methyl-N-vanillyl-6-noneamide) and resiniferatoxin inhibit the activation of NF-.kappa.B induced by different agents.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: November 9, 1999
    Assignee: Research Development Foundation
    Inventors: Bharat B. Aggarwal, Dezider Grunberger
  • Treatments for Diabetes Mellitus and Obesity
    Publication number: 20170105781
    Abstract: Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum. The ablation may be a mechanical, electrical, thermal, radiative, or chemical ablation and may in some cases target a sensory nerve. The methods may, in some cases, comprise the step of administering an active agent directly to the small intestine in the subject, in particular administering the active agent directly to the duodenum. The active agents useful in the treatments described herein include analgesic agents and, in particular, antinociceptive agents such as capsaicin, resiniferatoxin, and their analogues.
    Type: Application
    Filed: September 27, 2016
    Publication date: April 20, 2017
    Inventors: Pankaj Pasricha, Liansheng Liu
  • Treatments for Diabetes Mellitus and Obesity
    Publication number: 20240207208
    Abstract: Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum. The ablation may be a mechanical, electrical, thermal, radiative, or chemical ablation and may in some cases target a sensory nerve. The methods may, in some cases, comprise the step of administering an active agent directly to the small intestine in the subject, in particular administering the active agent directly to the duodenum. The active agents useful in the treatments described herein include analgesic agents and, in particular, antinociceptive agents such as capsaicin, resiniferatoxin, and their analogues.
    Type: Application
    Filed: March 8, 2024
    Publication date: June 27, 2024
    Inventors: Pankaj Pasricha, Liansheng Liu
  • Antagonists of the transient receptor potential vanilloid 1 and uses thereof
    Publication number: 20090012154
    Abstract: One of the major disabling symptoms of gastroparesis is nausea and vomiting which can be difficult to control with currently available treatments. It is postulated that signaling of gastrointestinal causes of nausea starts with activation of vagal afferent nerves that trigger the central emetic pathway. Most vagal afferent nerves are unmyelinated C-fibers, many of which express the vanilloid receptor TRPV1 and respond to capsaicin. Resiniferatoxin is a very potent capsaicin analogue that has a much more favorable ratio of desensitization to excitation than capsaicin leading to more effective desensitization without irritation. The present invention demonstrates that desensitization of TRPV1 responsive gastric sensory neurons would attenuate nausea and vomiting.
    Type: Application
    Filed: April 11, 2008
    Publication date: January 8, 2009
    Inventors: Pankaj J. Pasricha, Jiande Chen, Rami Hawari
  • Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin
    Publication number: 20150080460
    Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 19, 2015
    Applicant: Board of Regents of the University of Nebraska
    Inventors: Irving H. Zucker, Hanjun Wang
  • Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin
    Publication number: 20250082605
    Abstract: The present application provides methods for treating cardiovascular conditions. The methods can include administering a Transient Receptor Potential Vanilloid 1 (TRPV1) receptor agonist to an epidural space. The methods can be used to treat a variety of conditions such as hypertension, prehypertension, mild hypertension, severe hypertension, refractory hypertension, congestive heart failure and myocardial scarring.
    Type: Application
    Filed: March 29, 2024
    Publication date: March 13, 2025
    Applicant: Board of Regents of the University of Nebraska
    Inventors: Irving H. Zucker, Hanjun Wang
  • Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same
    Patent number: 6872748
    Abstract: The present invention is related to new vanilloid analogues containing resiniferatoxin pharmacophores, pharmaceutical compositions that have such analogues, and their uses as vanilloid receptor agonists and potent analgesics. The present invention provides a pharmaceutical composition for preventing, alleviating or treating pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neutopathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease or urgent urinary incontinence.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: March 29, 2005
    Assignee: Digital Biotech Co., Ltd.
    Inventor: Jee Woo Lee
  • Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
    Patent number: 11679075
    Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: June 20, 2023
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Irving H. Zucker, Hanjun Wang
  • Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin
    Publication number: 20200323771
    Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 15, 2020
    Applicant: Board of Regents of the University of Nebraska
    Inventors: Irving H. Zucker, Hanjun Wang
  • Treatments for Diabetes Mellitus and Obesity
    Publication number: 20200155218
    Abstract: Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum. The ablation may be a mechanical, electrical, thermal, radiative, or chemical ablation and may in some cases target a sensory nerve. The methods may, in some cases, comprise the step of administering an active agent directly to the small intestine in the subject, in particular administering the active agent directly to the duodenum. The active agents useful in the treatments described herein include analgesic agents and, in particular, antinociceptive agents such as capsaicin, resiniferatoxin, and their analogues.
    Type: Application
    Filed: January 22, 2020
    Publication date: May 21, 2020
    Inventors: Pankaj Pasricha, Liansheng Liu
  • Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
    Patent number: 9956166
    Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: May 1, 2018
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Irving H. Zucker, Hanjun Wang
  • Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same
    Publication number: 20040063786
    Abstract: The present invention is related to new vanilloid analogues containing resiniferatoxin pharmacophores, pharmaceutical compositions that have such analogues, and their uses as vanilloid receptor agonists and potent analgesics. The present invention provides a pharmaceutical composition for preventing, alleviating or treating pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neutopathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease or urgent urinary incontinence.
    Type: Application
    Filed: December 18, 2002
    Publication date: April 1, 2004
    Inventor: Jee Woo Lee
  • Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
    Patent number: 8110217
    Abstract: The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: February 7, 2012
    Assignee: University of Pittsburgh
    Inventors: Michael B. Chancellor, Pradeep Tyagi, Matthew O. Fraser, Yao-Chi Chuang, William C de Groat, Leaf Huang, Naoki Yoshimura
  • Sphingomyelin Liposomes for the Treatment of Hyperactive Bladder Disorders
    Publication number: 20120128762
    Abstract: The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 24, 2012
    Inventors: Michael B. Chancellor, Pradeep Tyagi, Matthew O. Fraser, Yao-Chi Chuang, William C. de Groat, Leaf Huang, Naoki Yoshimura
  • SPHINGOMYELIN LIPOSOMES FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDERS
    Publication number: 20170290773
    Abstract: The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 12, 2017
    Inventors: Michael B. Chancellor, Pradeep Tyagi, Matthew O. Fraser, Yao-Chi Chuang, William C. de Groat, Leaf Huang, Naoki Yoshimura
  • METHODS FOR ADMINISTRATION AND METHODS FOR TREATING CARDIOVASCULAR DISEASES WITH RESINIFERATOXIN
    Publication number: 20180140544
    Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.
    Type: Application
    Filed: August 3, 2017
    Publication date: May 24, 2018
    Applicant: Board of Regents of the University of Nebraska
    Inventors: Irving H. Zucker, Hanjun Wang
  • Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
    Patent number: 10729643
    Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: August 4, 2020
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Irving H. Zucker, Hanjun Wang
  • Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin
    Publication number: 20230277443
    Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.
    Type: Application
    Filed: May 16, 2023
    Publication date: September 7, 2023
    Applicant: Board of Regents of the University of Nebraska
    Inventors: Irving H. Zucker, Hanjun Wang
Narrow Results

Filter by US Classification